Merck: FDA won't OK its combo cholesterol drug now

March 5, 2012 By LINDA A. JOHNSON , AP Business Writer in Medications

(AP) -- Federal regulators have rejected Merck & Co.'s new combination cholesterol drug, which includes a generic version of the mega-blockbuster Lipitor - at least for now.

It's unclear how long the ruling, announced Monday, might delay approval of the drug, as the Food and Drug Administration is requiring additional study data on the compound. It combines generic Lipitor, the top-selling drug of all time, with Merck's cholesterol medicine Zetia.

Approval could boost Merck's sagging cholesterol franchise by essentially replacing its existing combo pill, Vytorin, with one likely to be seen as more powerful. Vytorin sales have been dwindling for a few years due to concerns about how well it works, and now Merck has to contend with patients possibly defecting to the generic versions of Pfizer Inc.'s Lipitor that came on the market at the end of November.

Merck said Monday that company officials will talk with the FDA to determine the next steps, adding that some new data expected later this year may address the FDA's concerns.

Wall Street seemed unfazed by the news, perhaps because the FDA increasingly asks for additional data before approving many new drugs. In morning trading, Merck shares were up 38 cents at $38.31.

The experimental drug, still known only as MK-0653C, contains medicines that fight high cholesterol in two different ways to reduce risk of heart attack and stroke.

Lipitor, known chemically as atorvastatin, is part of the widely used class of drugs called statins that reduce the amount of cholesterol naturally produced in the liver.

Zetia, on the other hand, reduces the amount of cholesterol absorbed from the food the patient eats.

Vytorin includes Zetia and an older statin, Merck's Zocor, also called simvastatin.

Sales of Vytorin and Zetia both were hurt when Merck, under pressure from a congressional probe, in early 2008 finally released unfavorable results from a study it had hoped would bolster Vytorin sales. Instead, it showed that Vytorin was no better at reducing plaque buildup in neck arteries than just Zocor, which had been available as a cheap generic since 2006. Zetia, also known as ezetimibe, is protected by patent in the U.S. until 2017.

Lipitor, which had peak sales of around $13 billion, is a more powerful statin then Zocor. That could mean that if the new combination is approved, it would be tried by at least some patients who have not been able to get their numbers to their goal with Vytorin or other treatments.

Meanwhile, last year Lipitor maker Pfizer sued, alleging Merck's application for the FDA to approve the Zetia-atorvastatin combination infringed on a Pfizer patent covering atorvastatin.

A Merck spokeswoman said Monday that the lawsuit "has the potential for holding up FDA approval of the product until" the first quarter of 2014.

©2012 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Study finds new pneumococcal vaccine appears to be as safe as previously used vaccine

The new 13-valent pneumococcal conjugate vaccine (PCV13) appears to be as safe as the previous version used prior to 2010, the 7-valent pneumococcal conjugate vaccine (PCV7), according to a Kaiser Permanente study published ...

Medications created 4 hours ago | popularity not rated yet | comments 0

Succesful results in developing oral vaccine against diarrhea

The University of Gothenburg Vaccine Research Institute (GUVAX) announces successful results in a placebo controlled phase I study of an oral, inactivated Escherichia coli diarrhea vaccine.

Medications created 7 hours ago | popularity not rated yet | comments 0

New sleeping pill poised to hit US markets

An experimental sleeping pill from US drug company Merck is effective at helping people fall and stay asleep, according to reviewers at the US Food and Drug Administration, which could soon approve the new drug.

Medications created 21 hours ago | popularity 4.2 / 5 (5) | comments 0

Global recommendations on child medicine

Transparent information on the evidence supporting global recommendations on paediatric medicines should be easily accessible in order to help policy makers decides on what drugs to include in their national drug lists, according ...

Medications created 22 hours ago | popularity not rated yet | comments 0

Analgesics prescribed more heavily to women than to men, study finds

Regardless of pain, social class or age, a woman is more likely to be prescribed pain-relieving drugs. A study published in Gaceta Sanitaria (Spanish health scientific journal) affirms that this phenomenon is inf ...

Medications created May 21, 2013 | popularity not rated yet | comments 0


Novel approach for influenza vaccination shows promise in early animal testing

A new approach for immunizing against influenza elicited a more potent immune response and broader protection than the currently licensed seasonal influenza vaccines when tested in mice and ferrets. The vaccine ...

Good marriage can buffer effects of dad's depression on young children

What effect does a father's depression have on his young son or daughter? When fathers report a high level of emotional intimacy in their marriage, their children benefit, said a University of Illinois study.

Hospitals profit when patients develop bloodstream infections

Johns Hopkins researchers report that hospitals may be reaping enormous income for patients whose hospital stays are complicated by preventable bloodstream infections contracted in their intensive care units.

Alleviating hunger in the US, it's a SNAP, researcher says

A University of Illinois researcher says that the cornerstone of our efforts to alleviate food insecurity should be to encourage more people to participate in the Supplemental Nutrition Assistance Program (SNAP) "because ...

Survey points out deficiencies in addictions training for medical residents

A 2012 survey of internal medicine residents at Massachusetts General Hospital (MGH) – one of the nation's leading teaching hospitals – found that more than half rated the training they had received in addiction and other ...

Obstructive sleep apnea associated with less visceral fat accumulation in women than men

A new study from researchers in Japan indicates that obstructive sleep apnea (OSA) is independently associated with visceral (abdominal) fat accumulation only in men, perhaps explaining gender differences in the impact of ...